A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

NCT02180789 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Interventions

DRUG: Tamsulosin OCAS

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]